IND Approval for Self-developed Product: CMS’s Innovative Drug Complement Factor B Inhibitor CMS-D017 is approved for Drug Clinical Trials for Complement – mediated Kidney Disease Indication

CMS-D017 is a novel selective small-molecule inhibitor of complement factor B（CFB）.By targeting and inhibiting CFB, it blocks abnormal activation of the alternative complement pathway, which reduces damage to target tissues and organs caused by the membrane attack complex, and effectively slows the progression of a range of complement dysregulation-related inflammatory responses and autoimmune diseases. CMS-D017 has demonstrated excellent efficacy and safety in preclinical studies. Besides paroxysmal nocturnal hemoglobinuria(which has been approved for drug clinical trials), it is also being developed for clinical use in the treatment of complement-mediated kidney diseases, including IgA nephropathy, idiopathic membranous nephropathy, lupus nephritis, C3 glomerulopathy, etc.; providing a potentially better therapeutic alternative for patients. Upon approval for marketing, CMS-D017 will synergize with the marketed innovative drug Velphoro (hyperphosphatemia of Chronic Kidney Disease) and the new drug currently under NDA review, Desidustat Tablets(renal anemia), in expert networks and market resources, collectively elevating the Group’s capabilities in the field of nephrology. […]